【摘要】 目的比较冠状动脉支架术(PCI)后国产氯吡格雷与进口氯吡格雷抗血小板治疗的安全性和有效性。方法收集2008年7月至2010年7月在滨州市中心医院行冠状动脉支架术患者132例,随机分为A组(国产氯吡格雷组,n=64)及B组(进口氯吡格雷组,n=68)。两组患者均采用标准阿司匹林、氯吡格雷联合抗血小板治疗至少1年。研究主要终点为随访1年时的心源性死亡、非致死性心肌梗死(MI)、脑卒中发生率。次要终点为随访1年时的因不良反应停药率。结果两组临床基线资料差异无统计学意义(P>0.05)。随访1年时,A组心源性死亡、非致死性Ml、脑卒中发生率(分别为1.6%、1.6%、0%)与B组(分别为1.5%、2.9%、0%)比较,差异无统计学意义(P>0.05)。A组出血事件发生率为3.1%,与B组1.5%比较,差异亦无统计学意义(P=0.284)。结论国产氯吡格雷与进口氯吡格雷均可有效地减少PCI术后主要终点及次要终点事件的发生率。更多还原

【Abstract】 Objective To explore the security and availability of antiplatelet therapy with 2 different brands of clopidogrel.Methods A total of 132 patients who underwent coronary stenting in Shandong Binzhou central hospital were enrolled,between July 2008 and July 2010.Patients were randomly assigned to group A(n=68)or group B(n=64).All patients were received standard antiplatelet therapy with aspirin and clopidogrel for at least 1 year.The primary endpoint was cardiac death,non-fatal myocardial infarction(MI)or stroke at 1 year.Sencondary endpoint was discontinuation rate due to adverse events.Results The baseline clinical characteristics was comparable between the two groups(P>0.05).No significant difference existed in cardiac death,non-fatal myocardial infarction(MI)or stroke at 1 year between the two groups at one-year follow-up(P>0.05).Also,no significant difference existed in the rate of hemorrhagic events between the two groups(P=0.284).Conclusion The security and availability of antiplatelet therapy had no difference between the two different brands of clopidogrel.更多还原